PRKCB and prostate carcinoma: Finally, the expression levels of PRKCB and SRD5A2 were validated in prostate cancer and adjacent normal tissues using clinical samples.<h4>Conclusion</h4>PRKCB and SRD5A2 were identified as potential immunological biomarkers and immunotherapeutic targets associated with immune cell infiltration in PCa, both of which were significantly downregulated in PCa tissues.